Ergomed Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Ergomed kazanç ve gelirinin sırasıyla yıllık 13.1% ve 9.4% oranında artması tahmin edilirken, EPS'nin yıllık 12.5% oranında büyümesi bekleniyor.

Anahtar bilgiler

13.1%

Kazanç büyüme oranı

12.5%

EPS büyüme oranı

Life Sciences kazanç büyümesi	26.2%
Gelir büyüme oranı	9.4%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Good
Son güncelleme	22 Jun 2023

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

XTRA:2EM - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (GBP Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2025	199	27	28	33	8
12/31/2024	179	23	25	30	9
12/31/2023	161	20	23	27	9
12/31/2022	145	15	13	15	N/A
9/30/2022	139	14	14	15	N/A
6/30/2022	132	13	15	16	N/A
3/31/2022	126	13	16	17	N/A
12/31/2021	119	13	18	19	N/A
9/30/2021	110	12	18	19	N/A
6/30/2021	102	12	17	18	N/A
3/31/2021	94	11	17	18	N/A
12/31/2020	86	10	17	18	N/A
9/30/2020	80	8	16	17	N/A
6/30/2020	73	6	16	17	N/A
3/31/2020	71	6	13	14	N/A
12/31/2019	68	6	11	12	N/A
9/30/2019	66	1	7	8	N/A
6/30/2019	64	-3	2	4	N/A
3/31/2019	59	-6	1	3	N/A
12/31/2018	54	-9	1	2	N/A
9/30/2018	54	-8	1	2	N/A
6/30/2018	54	-8	1	3	N/A
3/31/2018	51	-6	0	1	N/A
12/31/2017	48	-5	-1	0	N/A
9/30/2017	42	-2	-2	-1	N/A
6/30/2017	36	0	-4	-2	N/A
3/31/2017	33	0	-4	-2	N/A
12/31/2016	29	0	-3	-2	N/A
9/30/2016	31	1	N/A	-2	N/A
6/30/2016	28	1	N/A	-2	N/A
3/31/2016	29	1	N/A	-1	N/A
12/31/2015	30	2	N/A	0	N/A
9/30/2015	29	1	N/A	1	N/A
6/30/2015	28	1	N/A	2	N/A
3/31/2015	24	1	N/A	1	N/A
12/31/2014	21	1	N/A	1	N/A
9/30/2014	19	1	N/A	0	N/A
6/30/2014	16	1	N/A	-1	N/A
3/31/2014	16	1	N/A	0	N/A
12/31/2013	15	2	N/A	1	N/A
12/31/2012	15	0	N/A	1	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 2EM 'nin tahmini kazanç büyümesi (yıllık 13.1% ) tasarruf oranının ( 0.2% ) üzerindedir.

Kazançlar ve Piyasa: 2EM şirketinin kazançlarının (yıllık 13.1% ) German pazarından (yıllık 21% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 2EM şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: 2EM şirketinin gelirinin (yıllık 9.4% ) German pazarından (yıllık 5.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 2EM şirketinin gelirinin (yıllık 9.4% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 2EM 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Ergomed Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Ergomed plc Provides Earnings Forecast for the Full Year 2023

Ergomed plc Provides Revenue Guidance for the Year Ended 31 December 2021

Recent updates

Ergomed Submits an Application London Stock Exchange in Relation to the Cancellation of the Admission to Trading of its Shares on AIM, Expects to Take Place on 14 November 2023

Permira Advisers Ltd. completed the acquisition of Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others.

Ergomed Confirms Expected Scheme Timetable

Ergomed plc (AIM:ERGO) acquired Panacea Pharma Projects Limited from Stuart Colligon.

Permira Advisers Ltd. entered into a scheme of arrangement to acquire Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others for approximately £700 million.

Ergomed plc to Report Q2, 2023 Results on Sep 26, 2023

Ergomed plc Provides Earnings Forecast for the Full Year 2023

Ergomed plc, Annual General Meeting, Jun 22, 2023

Full year 2022 earnings released: EPS: UK£0.30 (vs UK£0.26 in FY 2021)

High number of new and inexperienced directors

Ergomed plc to Report Fiscal Year 2022 Results on Mar 21, 2023

High number of new and inexperienced directors

Ergomed plc Announces Board Changes, Effective 3 February 2023

Ergomed plc Announces Executive Changes

Ergomed plc Announces Directorate Changes

Ergomed Announces Two Senior Appointments to its Executive Team

Ergomed Strengthens Executive Management Team

Ergomed Strengthens Executive Management Team

Now 21% undervalued after recent price drop

First half 2022 earnings released: EPS: UK£0.15 (vs UK£0.14 in 1H 2021)

Ergomed plc to Report First Half, 2022 Results on Sep 27, 2022

Investor sentiment improved over the past week

Ergomed plc Appoints Anne Whitaker as Independent Non-Executive Director

Full year 2021 earnings released: EPS: UK£0.26 (vs UK£0.20 in FY 2020)

Ergomed plc, Annual General Meeting, Jun 10, 2022

Less than half of directors are independent

Now 21% undervalued

Full year 2021 earnings released: EPS: UK£0.26 (vs UK£0.20 in FY 2020)

Investor sentiment improved over the past week

John Dawson, Cbe Joins the Board of Ergomed plc as Independent Non-Executive Director and Chair of the Audit Committee

Investor sentiment improved over the past week

Ergomed plc to Report Fiscal Year 2021 Results on Mar 29, 2022

Pharmaust Limited Engages Ergomed Clinical Research Ltd to Commence Clinical Trials Testing the Anti-Viral Effects of Monepantel

Ergomed plc (AIM:ERGO) acquired Adamas Consulting Ltd. at an enterprise value of £24.2 million.

Ergomed plc Provides Revenue Guidance for the Year Ended 31 December 2021

First half 2021 earnings released: EPS UK£0.14 (vs UK£0.089 in 1H 2020)

Investor sentiment improved over the past week

Non-Executive Director has left the company

Investor sentiment improved over the past week

Full year 2020 earnings released

New 90-day high: €14.15

Ergomed plc to Report Fiscal Year 2020 Results on Mar 23, 2021

New 90-day high: €13.40

New 90-day high: €12.10

Ergomed plc (AIM:ERGO) acquired MedSource Consulting Inc. for $25 million.

New 90-day high: €9.76

New 90-day high: €9.58

New 90-day high - €7.68

New 90-day high - €6.86

Ergomed plc to Report First Half, 2020 Results on Sep 22, 2020

New 90-day high - €6.60

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin